MIMEDX Announces Publication in the Journal of Inflammation Focused on Immunomodulatory Effects of Purion® Processed Human Amniotic Membrane Allografts In Vitro

Rhea-AI Summary

MiMedx (NASDAQ: MDXG) announced a peer-reviewed publication on Dec 19, 2025 in the Journal of Inflammation reporting in vitro findings for Purion processed dehydrated (DHACM) and lyophilized (LHACM) human amnion chorion membrane allografts.

The study found that DHACM and LHACM exhibit multifactorial immunomodulatory effects on inflammatory monocytes and macrophages and enhance pro-reparative functions including efferocytosis and cell survival, suggesting potential to help reset the wound-healing cascade in complex wounds characterized by persistent inflammation.

Market Reality Check

$6.48 Last Close

Volume Volume 955,635 is 1.24x the 20-day average of 772,472 shares. normal

Technical Price at 7.25 is trading above the 200-day MA of 6.96 and below the 9.71 52-week high.

Peers on Argus

No peers with momentum or same-day headlines were detected, suggesting a stock-specific response to the new immunomodulatory data.

Market Pulse Summary

This announcement highlights new in vitro evidence that Purion-processed DHACM and LHACM allografts exert multifactorial immunomodulatory effects on monocytes and macrophages, supporting the wound-healing cascade. With the stock already trading above its 200-day MA at 6.96 yet below its 9.71 52-week high, investors may track how this mechanistic research complements existing clinical data and any future outcomes linked to complex, inflammation-driven wounds.

Key Terms

immunomodulatory medical

"exhibited immunomodulatory properties that correspond with the beneficial outcomes"

Immunomodulatory describes a drug, therapy, or compound that changes how the immune system responds—either boosting, calming, or redirecting its activity. For investors, immunomodulatory products matter because they target many large markets (autoimmune diseases, infections, cancer) and carry distinct safety, trial-design and regulatory risks; think of them as a thermostat for the immune system, where small adjustments can strongly affect effectiveness, side effects and approval chances.

allografts medical

"Purion processed human amniotic membrane allografts In Vitro"

Allografts are medical implants or tissue transplants taken from one person and used in another to replace or repair damaged bone, skin, or other tissues — think of them as biological replacement parts donated by another human. They matter to investors because their safety, availability, regulatory approval, reimbursement rules, and infection or rejection risks directly affect healthcare companies’ sales, costs and legal exposure, which in turn influence revenue and valuation.

efferocytosis medical

"enhancing pro-reparative functions including efferocytosis and cell survival"

Efferocytosis is the biological process by which the body’s cleanup cells identify and remove dead or dying cells, similar to a sanitation crew clearing away trash so tissues can function smoothly. For investors, it matters because drugs or tests that boost or measure this cleanup can change outcomes in inflammatory, autoimmune and cardiovascular diseases, affecting clinical trial success, regulatory approval and market value.

monocyte medical

"regulate critical functions of inflammatory monocyte and macrophage biology"

A monocyte is a type of white blood cell that circulates in the bloodstream and acts like a mobile security guard and cleanup crew, moving to sites of infection or injury to engulf and digest harmful substances and dead cells. For investors, monocyte levels and behavior matter because they serve as measurable markers in drug development, diagnostic tests and safety monitoring—changes can signal disease activity, treatment effect or side‑effect risks that affect clinical trial outcomes and market value.

macrophage medical

"inflammatory monocyte and macrophage biology, while enhancing pro-reparative"

Macrophages are immune cells that act like the body's cleanup crew and security guards, consuming pathogens, debris, and damaged cells and signaling other immune responses. They matter to investors because many drugs, diagnostics, and medical technologies target or measure macrophage activity to treat infections, inflammation, cancer, or tissue repair, so changes in research, regulatory approvals, or trial results involving macrophages can materially affect healthcare company prospects and valuations.

AI-generated analysis. Not financial advice.

Study investigates the influence of MIMEDX DHACM and LHACM products on inflammatory response, which supports the healing cascade and tissue repair

MARIETTA, Ga., Dec. 19, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced the latest addition to its industry-leading body of scientific and clinical evidence supporting the use of its dehydrated human amnion chorion membrane (DHACM) and lyophilized human amnion chorion membrane (LHACM) products, in the Journal of Inflammation. The article, “Immunomodulatory Effects of Purion Processed Human Amniotic Membrane Allografts In Vitro” can be accessed online here.

“Our team has once again demonstrated MIMEDX’s commitment to generating robust and impactful peer-reviewed research, highlighting the capacity of our technology and the products that are derived from our proprietary tissue processing methodology,” stated Joseph H. Capper, MIMEDX Chief Executive Officer. “In this latest publication, we were pleased to find that our DHACM and LHACM allografts exhibited immunomodulatory properties that correspond with the beneficial outcomes we observe in the clinical setting. This study marks another important contribution to our comprehensive library of clinical and scientific research, which has positioned us favorably in our marketplace, especially considering the renewed emphasis the pending Local Coverage Determinations (LCDs) place on the production of high-quality evidence.”

The study evaluated two configurations of Purion processed placental allografts, DHACM and LHACM, for their ability to regulate key cell types in the inflammatory cascade. The findings illustrate a multifactorial immunomodulatory effect whereby DHACM and LHACM allografts regulate critical functions of inflammatory monocyte and macrophage biology, while enhancing pro-reparative functions including efferocytosis and cell survival. This study is highly relevant, as complex wounds are frequently characterized by persistent inflammation within the wound bed, which contributes to chronicity and poor clinical outcomes; therefore, DHACM and LHACM represent promising interventions to help restore and reset the normal wound-healing cascade.

About MIMEDX
MIMEDX is a pioneer and leader focused on helping humans heal. With more than a decade of helping clinicians manage chronic and other hard-to-heal wounds, MIMEDX provides a leading portfolio of products for applications in the wound care, burn, and surgical sectors of healthcare. The Company’s vision is to be the leading global provider of healing solutions through relentless innovation to restore quality of life. For additional information, please visit www.mimedx.com.

Contact:
Matt Notarianni
Investor Relations
470-304-7291
mnotarianni@mimedx.com

FAQ

What did MiMedx (MDXG) publish on December 19, 2025?

MiMedx published an in vitro study in the Journal of Inflammation on Purion processed DHACM and LHACM allografts showing immunomodulatory effects.

How do DHACM and LHACM allografts affect inflammation according to the MDXG study?

The study reports DHACM and LHACM regulate inflammatory monocyte and macrophage functions and enhance efferocytosis and cell survival.

Does the MDXG Journal of Inflammation paper show clinical trial results?

No, the publication reports in vitro laboratory findings rather than clinical trial outcomes.

Why are the DHACM and LHACM findings relevant for complex wounds for MDXG investors?

The findings suggest these allografts may help address persistent inflammation, a known factor in chronic wound non‑healing.

What products were evaluated in the MiMedx (MDXG) in vitro study?

The study evaluated Purion processed dehydrated human amnion chorion membrane (DHACM) and lyophilized human amnion chorion membrane (LHACM).

Where was the MDXG study published and how can investors view it?

The study was published in the Journal of Inflammation and is available online through the journal's publication site.